Lung Adenocarcinoma Invasion Genomics

肺腺癌侵袭基因组学

• 批准号: 8506870
• 负责人: PIERRE P. MASSION
• 金额: $ 60.39万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8506870
• 关键词: Address; Adenocarcinoma; Animal Model; Basement membrane; Biological; Biological Assay; Biological Markers; Biology; Biopsy Specimen; Blood Vessels; Cell Mobility; Cell-Cell Adhesion; Cells; Chromosomes; Clinical; Clinical Management; Coculture Techniques; Complex; DNA; DNA Microarray Chip; DNA copy number; Data; Data Analyses; Data Set; Diagnosis; Diagnostic; Diagnostic Neoplasm Staging; Disease; Early treatment; Epidemiology; Epidermal Growth Factor Receptor; Excision; Extravasation; Fine needle aspiration biopsy; Fluorescent in Situ Hybridization; Gene Amplification; Gene Expression; Gene Expression Alteration; Gene Expression Profiling; Gene Targeting; Genes; Genetic Transcription; Genomics; Goals; Heterogeneity; Histologic; Indolent; Lung; Lung Adenocarcinoma; Lung Neoplasms; Malignant Neoplasms; Malignant neoplasm of lung; Measurement; Measures; Mediating; Messenger RNA; Molecular; Mutation; Needle biopsy procedure; Neoplasm Metastasis; Nodule; Outcome; Patients; Phase; Phenotype; Process; Property; RNA; RNA Interference; Research; Resected; Risk; Role; Solid; Somatic Mutation; Specimen; Staging; Stromal Cells; System; Testing; The Cancer Genome Atlas; Therapeutic; Tissue Microarray; Tissues; Tumor stage; Validation; advanced disease; angiogenesis; cell motility; clinically relevant; cohort; exome sequencing; experience; improved; innovation; multidisciplinary; neoplastic cell; novel; prospective; public health relevance; repository; research clinical testing; tumor; tumor progression

DESCRIPTION (provided by applicant): Our project focuses on characterizing the molecular mechanisms important for the acquisition of invasion in lung adenocarcinoma. Our research has focused on characterizing the molecular mechanisms important for invasion, the initial step of metastasis. Studies from our group and others indicate that clinical outcomes for patients with early stage lung adenocarcinoma are influenced by histological invasiveness. Deciphering the molecular processes underlying the acquisition of invasiveness promises to have increasing importance as we see a shift in the epidemiology of lung cancer towards early, and in some cases, not yet invasive disease. An improved understanding of the biological properties of these tumors will enhance the clinical management of early stage lung cancer, including directing the extent of resection for small lung adenocarcinoma tumors. Our dataset is enriched for early stage non-invasive adenocarcinoma (AIS, formerly called BAC) tumors that are not well represented in genomics repositories such as The Cancer Genome Atlas (TCGA). Our preliminary gene expression profiling results from tumor cells suggest that focal chromosomal copy number increase is important in mediating the acquisition of invasion in lung adenocarcinoma. This innovative discovery is the focus of this multidisciplinary, multi-institutional project to expand our genomics examination of focal somatic copy number alterations, examine the role of stromal influences on invasion, investigate the diagnostic and therapeutic implications of gene amplification, and to understand the mechanisms that repress invasion in AIS and promote invasion in adenocarcinoma. Using well characterized cohorts of lung adenocarcinoma specimens, we will use RNA and DNA microarrays, whole exome sequencing, and fluorescent in situ hybridization to test the hypothesis that genomic loci with integrated alterations of copy number and mRNA levels are important for the acquisition of invasion and metastasis capacity in lung adenocarcinoma. Upon validation in resected specimens, these loci will be brought forth for prospective clinical testing in resected tumor specimens and in fine needle aspirates acquired from early stage lung adenocarcinoma tumors. Our long term goal is to develop biomarkers that will stratify risk before or after resection of tumors that are homogenous radiographically or histologically, respectively.

描述（由申请人提供）：我们的项目重点是表征肺腺癌侵袭性获得的重要分子机制。我们的研究集中在表征对侵袭重要的分子机制，即转移的最初步骤。本研究组和其他研究表明，早期肺腺癌患者的临床结局受组织学侵袭性的影响。随着我们看到肺癌的流行病学向早期（在某些情况下还不是侵袭性疾病）转变，破译获得侵袭性的分子过程将变得越来越重要。对这些肿瘤生物学特性的进一步了解将增强早期肺癌的临床管理，包括指导小肺腺癌肿瘤的切除范围。我们的数据集富集了早期非侵袭性腺癌（AIS，以前称为BAC）肿瘤，这些肿瘤在基因组学知识库（如癌症基因组图谱（TCGA））中没有很好的代表性。我们初步的肿瘤细胞基因表达谱分析结果表明，局部染色体拷贝数增加在介导肺腺癌侵袭性的获得中是重要的。这一创新性发现是这个多学科，多机构项目的重点，以扩大我们对局灶性体细胞拷贝数改变的基因组学检查，检查基质对侵袭的影响，研究基因扩增的诊断和治疗意义，并了解AIS中抑制侵袭和促进腺癌侵袭的机制。我们将使用RNA和DNA微阵列、全外显子测序和荧光原位杂交技术，利用肺腺癌标本的特征队列，检验基因组位点拷贝数和mRNA水平的综合改变对肺腺癌侵袭和转移能力的获得很重要这一假设。在切除标本中验证后，这些位点将用于切除肿瘤标本和从早期肺腺癌肿瘤中获得的细针抽吸物中的前瞻性临床试验。我们的长期目标是开发生物标志物，分别在放射学或组织学上均质的肿瘤切除前后对风险进行分层。